Introduction {#s1}
============

The epidermal growth factor receptor (EGFR) and its downstream signalling pathways are involved in the development and progression of several human tumours including colorectal cancer (CRC).[@R1] Activated signalling pathways including the RAS-RAF-BRAF-MAPK and the phosphatidylinositol 3-kinase (PI3K)-Akt pathways are key drivers of tumour growth and progression.[@R4] Patients with CRC can be successfully treated with anti-EGFR monoclonal antibody therapies, such as panitumumab or cetuximab, which work by disrupting EGFR signals[@R6]---provided the tumours do not have mutations in EGFR signalling pathways.[@R11] Testing patients for specific mutations that are linked to lack of response to EGFR blockade prior to commencing therapy ensures they receive the most appropriate treatment, and that treatment benefits, adverse effects and costs will be optimised.

Reduced anti-EGFR treatment efficacy was initially thought to be the result of mutations within *KRAS* exon 2 (codons 12 and 13). Therefore, *KRAS* genotyping was routinely used to stratify patients with CRC into those likely to respond to anti-EGFR therapy and those unlikely to respond. Further mutations causing resistance to anti-EGFR therapy were subsequently discovered through two large clinical studies (PRIME and CRYSTAL) which showed that 14%--17% wild-type (WT) *KRAS* exon 2 individuals actually responded poorly to anti-EGFR therapy.[@R9] It is now known that resistance to therapy has a range of genetic causes: mutations in *KRAS* (exons 2, 3 and 4) and *NRAS* (exons 2, 3 and 4) are found in 40%--45% and 5%--10% of patients, respectively.[@R5] *BRAF* V600E mutation is detected in 4%--18% of CRC cases and is prognostic of outcomes, but, in contrast to KRAS which is predictive of response is not used to guide anti-EGFR treatment.[@R16]

The Idylla System (Biocartis, Mechelen, Belgium) is a fully automated, real-time PCR-based molecular diagnostics system.[@R20] The Idylla NRAS-BRAF mutation test is a novel *in vitro* diagnostic medical device (IVD) for the qualitative detection of mutations in codons 12, 13, 59, 61, 117 and 146 of the *NRAS* oncogene and codon 600 in the *BRAF* oncogene in formalin-fixed paraffin-embedded (FFPE) human malignant CRC tissue. This non-randomised study, was a clinical performance evaluation of the Idylla NRAS-BRAF mutation test with retrospectively collected samples and prospectively planned data generation.

Materials and methods {#s2}
=====================

The Idylla platform {#s2a}
-------------------

The Idylla molecular diagnostic platform is a fully automated, allele-specific real-time PCR-based molecular diagnostic system.[@R20] It combines sample preparation with PCR thermocycling to detect molecular targets from a variety of solid and liquid samples including FFPE slices. Briefly, FFPE tissue sections are placed directly into the Idylla system cartridge, with no preprocessing. The cartridge is then inserted into the Idylla platform, where high-intensity focused ultrasound (HiFu) technology, buffers, reagents and heat induces deparaffinisation, tissue disruption, cell lysis and subsequent release of nucleic acid. Allele-specific primers and fluorescent probes then perform real-time PCR amplification and mutation detection. All required consumables are provided in the cartridge, and the Idylla Console and instruments are CE marked.

The Idylla NRAS-BRAF mutation test {#s2b}
----------------------------------

The Idylla NRAS-BRAF mutation test uses allele-specific multiplex PCR reactions to amplify 23 mutations in codons 12, 13, 59, 61, 117, 146 of the *NRAS* oncogene and codon 600 of the *BRAF* oncogene. A set of parameters describing the generated PCR curves are determined by the Idylla software, for example, ΔCq value (calculated as the difference between the quantification cycle value (Cq) of the gene control signal and the Cq of the mutant signal). A sample is classified as mutation positive if the parameters of the PCR curve generated are within the validated range. Otherwise the sample is reported as being mutation negative, that is, WT. [Table 1](#T1){ref-type="table"} lists the mutations detected by the test.

###### 

*NRAS* and *BRAF* mutations detected by the Idylla NRAS-BRAF mutation test

  Gene     Exon            Codon                 Mutation              Protein         Nucleotide change   Genetic call
  -------- --------------- --------------------- --------------------- --------------- ------------------- --------------
  *NRAS*   2               12                    G12D                  p.(Gly12Asp)    c.35G\>A            G12D
  G12C     p.(Gly12Cys)    c.34G\>T              G12C                                                      
  G12S     p.(Gly12Ser)    c.34G\>A              G12S                                                      
  G12A     p.(Gly12Ala)    c.35G\>C              G12A/V                                                    
  G12V     p.(Gly12Val)    c.35G\>T                                                                        
  13       G13D            p.(Gly13Asp)          c.38G\>A              G13D                                
  G13R     p.(Gly12Arg)    c.37G\>C              G12R/V                                                    
  G12V     p.(Gly13Va)     c.38G\>T                                                                        
  3        59              A59T                  p.(Ala59Thr)          c.175G\>A       A59T                
  61       Q61K            p.(Gln61Lys)          c.181A\>G             Q61K                                
  Q61R     p.(Gln61Arg)    c.182A\>G             Q61R                                                      
  Q61L     p.(Gln61Leu)    c.182A\>T             Q61L                                                      
  Q61H     p.(Gln61His)    c.183A\>T             Q61H                                                      
  Q61H     p.(Gln61His)    c.183A\>T                                                                       
  4        117             K117N                 p.(Lys117Asn)         c.351G\>C       K11N                
           K117N           p.(Lys117Asn)         c.351G\>T                                                 
           A146T           p.(Ala146Thr)         c.426G\>A             A146T/V                             
           A146V           p.(Ala146Val)         c.437C\>T                                                 
  *BRAF*   15              600                   V600E                 p.(Val600Glu)   c.1799T\>A          V600E/D
  V600E    p.(Val600Glu)   c.1799_1800delinsAA                                                             
  V600D    p.(Val600Asp)   c.1799_1800delinsAC                                                             
  600      V600K           p.(Val600Lys)         c.1798_1799delinsAA   V600K/R                             
  V600R    p.(Val600Arg)   c.1798_1799delinsAA                                                             

The results obtained from the Idylla NRAS-BRAF mutation test during this study were not used for clinical or diagnostic purposes and were not made available to patients or their clinicians.

The comparator test {#s2c}
-------------------

The *NRAS* and *BRAF* mutation status for each FFPE tissue sample was assessed using the MassARRAY System (Agena Bioscience). Existing test results were used if the comparator test had been performed within 2 years of the start of this study and no further slides or slices had been taken from the source FFPE block. H&E slides were taken at the start and end of block slicing to confirm sample homogeneity. If the sample block had been cut since the initial comparator test analysis, newly prepared alternating slides/slices were taken to rerun the comparator test. To reduce the risk of bias, different operators performed testing on the MassARRAY System and the Idylla NRAS-BRAF mutation test.

The Agena MassARRAY mutation test {#s2d}
---------------------------------

The Agena MassARRAY mutation test used in this study is a Laboratory Developed Test which is within the scope of the ISO 15189 accreditation held by NewGene Ltd, and is routinely used clinically. Samples with known mutation profiles, as used during clinical validation of the assay for ISO 15189 accreditation, were used as positive controls. 'No template' reactions, prepared with deionised H~2~O in place of template DNA were used as controls for non-specific amplification.

MassARRAY utilises the primer extension analytical method to determine the presence or absence of single nucleotide polymorphisms (SNPs) which cause specific mutations in the protein encoded by a gene. First, target region-specific PCR with short amplicons is used to amplify the DNA encoding the target sequence. These PCR products are then probed for the presence of the mutation of interest using an oligonucleotide which is complementary to the region immediately adjacent to the SNP location. This is then extended by only one base, using 2\',3\' dideoxynucleotides (ddNTPs); the ddNTP which terminates the oligonucleotide chain corresponds to the base code at the SNP location. A matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry system is then used to differentiate between oligonucleotide species on the basis of their differing masses, identifying the various SNP bases present at that location and also quantifying the relative allelic frequency of the mutant sequence versus the WT.

Study size estimation {#s2e}
---------------------

The number of samples required for a diagnostic agreement study with 80% power and expected agreement rate of 95% is 188. To allow for invalid runs and samples, the target number of FFPE tumour tissue blocks to be tested was set at 250. At least 30 valid FFPE samples with known *NRAS* mutations, at least 30 samples with known *BRAF* mutations, and up to 190 samples with WT *KRAS* were planned to be included.

Tissue selection criteria and process {#s2f}
-------------------------------------

The inclusion criteria for samples can be found in [box 1](#B1){ref-type="boxed-text"}. Samples were obtained from two centres: The Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust (UK; n=113), and the Institute of Pathology, Aarhus University Hospital (Denmark; n=156). All available samples were entered into the study. [Figure 1](#F1){ref-type="fig"} shows how FFPE tissue samples were prepared for use in the Idylla NRAS-BRAF mutation test.

![Formalin-fixed paraffin-embedded (FFPE) sample preparation algorithm prior to Idylla NRAS-BRAF mutation test. Histologically confirmed, retrospectively collected FFPE colorectal cancer tissue samples were identified and tissue sections 5 or 10 µm thick were sampled as close as possible (within the same FFPE block) to the sections used for reference testing. Prior to analysis, the tumour content and area were determined on a H&E slide by a consultant histopathologist at both sites. If required, macrodissections were performed to ensure tumour nuclei content of more than 10% in the sample for analysis. The volume of material was specified to ensure that there was sufficient for the assay while not overloading the device.](jclinpath-2017-204629f01){#F1}

###### Sample selection criteria

Formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples were included if they were:

-   Obtained from male or female patients≥18 years of age

-   Approved for investigational purposes according to the applicable laws

-   Histologically confirmed to be primary or metastatic malignant CRC

-   Fixed in formalin for a maximum time of 48 hours

-   Less than 10 years old and had been stored at ambient conditions

-   Stored at room temperature for not more than 60 days prior to Idylla testing

CRC samples were excluded if:

-   The patient declined to provide their sample to third parties for research purposes

The protocol specified that samples should have at least 10% of their content identified as tumorous cells because the clinical importance of results (concordant or discrepant) from samples with very low proportions of tumorous cells could be debatable.

Diagnostic performance measurements {#s2g}
-----------------------------------

Baseline testing {#s2h}
----------------

No discrepancies were observed between the original results and the repeat results when retesting with the MassARRAY was performed on specimens that had originally been tested with other devices.

Percentage agreement {#s2i}
--------------------

As it is not feasible to set-up a study with large numbers of each individual mutant, the performance of the Idylla NRAS-BRAF mutation test was scored based on total agreement. Overall agreement (% total agreement), and negative and positive agreements were determined together with their 95% one-sided CIs. Overall agreement was defined as the proportion of concordant results in all results. Positive agreement was defined as the proportion of concordant results in positive Idylla results. Negative agreement was defined as the proportion of concordant results in negative Idylla results.

Discordant by design results {#s2j}
----------------------------

The Idylla NRAS-BRAF panel detects 18 *NRAS* mutations and 5 *BRAF* mutations ([table 1](#T1){ref-type="table"}), while the MassARRAY *NRAS-BRAF* panel detects 25 *NRAS* mutations and provides a *BRAF* V600E result as a generic call rather than distinguishing between V600E/D or V600K/R. The seven additional *NRAS* mutations detected by the MassARRAY but not by the Idylla NRAS-BRAF mutation test panel include G12R, G13C, G13S, G13A, Q61P and Q61E. Samples that were anticipated to produce discordant results because of design differences in the Idylla and MassARRAY systems were classed as 'discordant by design' and were excluded from analysis.

Investigation of discordant results {#s2k}
-----------------------------------

Discordant results were further investigated by using droplet digital PCR as a second comparator test to evaluate the accuracy of the Idylla result. Droplet digital PCR was performed on a QX100TM system (Bio-Rad Laboratories, Hercules, California, USA) according to the instructions of the manufacturer.

Results {#s3}
=======

Samples included {#s3a}
----------------

Two hundred and sixty-nine FFPE CRC samples were initially identified for the study ([figure 2](#F2){ref-type="fig"}), and 242 samples included in the performance evaluation. Twenty-seven FFPE samples were excluded because they failed to meet the inclusion criteria. The most common reason for exclusion was insufficient sample quantity (n=11). One FFPE sample was excluded because it was classified as discordant by design. Seven samples resulted in a failed run, three of which were due to insufficient sample (assay failure) and four of which were due to instrument errors (system failure). This equates to assay and system failure rates of 1.24% and 1.74%, respectively. All invalid and error runs were successfully repeated and included in the agreement analysis as specified in the protocol. Samples included in the study ranged from blocks of tumour from resections (198) to small diagnostic core biopsies (44). Macrodissection was required in 126 samples. The proportions of tumour ranged from 20% to 60% in sections without macrodissection, and from 10% to 75% in sections requiring macrodissection.

![Process of enrolling samples into the study.](jclinpath-2017-204629f02){#F2}

The photomicrographs in [figure 3](#F3){ref-type="fig"} are from samples which show extensive mucinosis (A) extensive necrosis (B) and a small core biopsy (C). The Idylla NRAS-BRAF mutation test was able to detect mutations in all such samples.

![Photomicrograph of tumour samples used for performance evaluation study. (A) sample with extensive mucinosis; (B) sample with extensive necrosis; (C) sample from small core biopsy of metastatic colon adenocarcinoma in the liver. The core was divided lengthways before embedding and the total section area was 25 mm^2^, the minimum specified in the protocol. The sample tested positive in both platforms without macrodissection and included solid adenocarcinoma (top left) normal liver (top right) and mucinous stroma (lower core).](jclinpath-2017-204629f03){#F3}

Baseline demographic and clinical characteristics {#s3b}
-------------------------------------------------

The final study population demographics and clinical characteristics are presented in [table 2](#T2){ref-type="table"}. Gender representation was balanced between males and females (54% and 46%, respectively). The mean age at tumour collection was 67.6 years (range: 24--96 years). The majority of samples (91%) were of primary tumour tissues originating from the colon. The remaining samples were from metastatic deposits originated in the liver (3%) or another (6%) location. All samples were histologically confirmed as malignant CRC; 85% were *KRAS* WT, 15% had an *NRAS* mutation and 21% had a *BRAF* mutation.

###### 

Baseline demographic and clinical characteristics for participants with valid test results

  ------------------------------------------------------ -----------------
  Gender                                                 
   Male                                                  131 (54%)
   Female                                                111 (46%)
  Mean age (years) at tumour tissue collection date      67.6 (SD 10.96)
  Histologically confirmed malignant colorectal cancer   242 (100%)
  Tissue location                                        
   Primary                                               220 (91%)
   Metastatic (liver)                                    7 (3%)
   Metastatic (other)                                    15 (6%)
  ------------------------------------------------------ -----------------

Clinical performance of the Idylla NRAS-BRAF mutation test {#s3c}
----------------------------------------------------------

The *NRAS* and *BRAF* mutational status of 242 retrospectively collected FFPE CRC samples was tested with the NRAS-BRAF mutation test. Results were compared with assessments made by the MassARRAY comparator reference test. Of the 242 FFPE samples analysed by the NRAS-BRAF Mutation Test, 36 tested positive for a mutation in *NRAS*, and in 205 cases, no *NRAS* mutation was found ([table 3](#T3){ref-type="table"}). As presented in [table 4](#T4){ref-type="table"}, results obtained by the NRAS-BRAF mutation test for *NRAS* testing were in agreement with the results obtained from the MassARRAY comparator reference test for 241 of 242 samples, resulting in an overall concordance of 99.59%, (lower bound of one-sided 95% CI=98.17%) with positive agreement of 100% (lower bound of one-sided 95% CI=93.0%) and a negative agreement of 99.51% (lower bound of one-sided 95% CI=97.85%).

###### 

Mutation concordance analysis for the Idylla NRAS-BRAF mutation test for *NRAS* compared with MassARRAY. Table entries on the diagonal with orange shading are concordant results. The one discordant result, G12D with Idylla and WT with MassARRAY, is shaded light blue and discussed in the text

  Idylla    MassARRAY                                            
  --------- ----------- --- --- ---- --- --- --- --- --- --- --- -----
  G12A/V    1           4   0   0    0   0   0   0   0   0   0   0
  G12C      0           0   2   0    0   0   0   0   0   0   0   0
  G12D      0           0   0   11   0   0   0   0   0   0   0   1\*
  G12S      0           0   0   0    0   0   0   0   0   0   0   0
  G13D      0           0   0   0    0   1   0   0   0   0   0   0
  Q61H      0           0   0   0    0   0   1   0   0   0   0   0
  Q61K      0           0   0   0    0   0   0   7   0   0   0   0
  Q61L      0           0   0   0    0   0   0   0   3   0   0   0
  G61R      0           0   0   0    0   0   0   0   0   6   0   0
  A146T/V   0           0   0   0    0   0   0   0   0   0   0   0
  WT        0           0   0   0    0   0   0   0   0   0       205

The orange entries on the diagonal highlight the correspondence between the MassARRAY and Idylla results. The one discrepant result has a light blue background.

\*ddPCR confirmed the G12D result (\<5% allelic frequency).

WT, wild type.

###### 

Idylla NRAS-BRAF mutation test results compared with the reference test (MassARRAY) results

  ------------------------------------------ -------------------------------------------------- -------------------------------------------------- -----
  \(a\) *NRAS* testing                                                                                                                             

  Idylla                                                                                        MassARRAY                                          

  Mutation                                   No mutation                                        Total                                              

  Mutation                                   36                                                 1                                                  37

  No mutation                                0                                                  205                                                205

  Total                                      36                                                 206                                                242

  Idylla performance                         Overall agreement                                  241/242\                                           
                                                                                                (99.59%, lower bound of one-sided 95% CI=98.17%)   

  Positive agreement                         36/36\                                                                                                
                                             (100%, lower bound of one-sided 95% CI=93.0%)                                                         

  Negative agreement                         205/206\                                                                                              
                                             (99.51%, lower bound of one-sided 95% CI=97.85%)                                                      

  \(b\) *BRAF* testing                                                                                                                             

  Idylla                                                                                        MassARRAY                                          

  Mutation *BRAF* c.1799T\>A p.(Val600Glu)   No mutation                                        Total                                              

  Mutation *BRAF* c.1799T\>A p.(Val600Glu)   52                                                 0                                                  52

  No mutation                                0                                                  190                                                190

  Total                                      52                                                 190                                                242

  Idylla performance                         Overall agreement                                  242/242\                                           
                                                                                                (100%, lower bound of one-sided 95% CI=98.89%)     

  Positive agreement                         52/52\                                                                                                
                                             (100%, lower bound of one-sided 95% CI=95.05%)                                                        

  Negative agreement                         190/190\                                                                                              
                                             (100%, lower bound of one-sided 95% CI=98.60%)                                                        
  ------------------------------------------ -------------------------------------------------- -------------------------------------------------- -----

Of the 242 FFPE samples, 52 tested positive for BRAF V600E/D mutation; no mutation was found in 190 cases. Results obtained by the NRAS-BRAF mutation test for *BRAF* testing were fully in agreement with the results obtained from the MassARRAY comparator reference test resulting in an overall concordance of 100% (lower bound of one-sided 95% CI=98.89%) ([table 4](#T4){ref-type="table"}).

Discordant result {#s3d}
-----------------

In one case, a G12D *NRAS* mutation was detected by the NRAS-BRAF mutation test but not by the MassARRAY comparator reference test ([tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). The *NRAS* G12D result was confirmed to be a true positive by ddPCR analysis with an allelic frequency of around 0.5%, which is well below the 5% limit of detection of the MassARRAY system ([table 5](#T5){ref-type="table"}).

###### 

Discordant result between Idylla NRAS-BRAF mutation test and MassARRAY reference method

  Sample no   Tissue    Age of block   No of FFPE tissue sections   Total tissue area (mm^2^)   Tumour cells (%)   Macrodissection   Idylla *NRAS* result   Further analysis method   Further analysis and final classification
  ----------- --------- -------------- ---------------------------- --------------------------- ------------------ ----------------- ---------------------- ------------------------- -------------------------------------------
  A050        Primary   \<1 year       1                            225                         30                 No                G12D                   ddPCR                     G12D (TP)

ddPCR, droplet digital PCR; NMD, no mutation detected; FFPE, formalin-fixed paraffin-embedded; FP, false positive; TP, true positive.

Discussion {#s4}
==========

The importance of testing for *NRAS* and *BRAF* mutations in tumours from patients with CRC is reflected in recent clinical practice recommendations of the American Society of Clinical Oncology[@R27] and the European Society for Medical Oncology.[@R28] *NRAS* mutations in colorectal tumours are associated with poor response to anti-EGFR therapy while *BRAF* mutations are associated with reduced survival.[@R29] Evidence-based guidelines therefore recommend *NRAS* (predictive) testing to guide treatment decisions and *BRAF* (prognostic) testing to provide information on outcomes.[@R27]

The performance of the Idylla platform has been previously reported in various validation studies.[@R23] In the present study, results from the Idylla NRAS-BRAF mutation test, which can detect 18 *NRAS* and five *BRAF* clinically relevant and actionable mutation targets, were compared with results obtained from *NRAS* and *BRAF* mutation testing by the MassARRAY.

There was greater than 99.5% concordance between the Idylla platform results and MassArray findings for *NRAS* and *BRAF* testing. Droplet digital PCR testing of the one discordant result confirmed the Idylla identification. One plausible explanation for this finding is that Idylla may have a lower limit of detection than the MassARRAY reference test; other possible explanations include test error and sample error.

Both the Idylla platform and MassARRAY methods were highly sensitive, and mutations could be reliably detected in small core biopsies and in samples with extensive mucinosis or necrosis.

As with other products based on similar technologies that identify specific mutations, mutations that are not intended to be detected will not be detected. However, these technologies in general, and the Idylla system, in particular, have the advantage of being able to readily update their assays to include mutations newly recognised as being clinically important, although revalidation for CE marking may be required.

In conclusion, the Idylla NRAS-BRAF mutation test is a fully automated and integrated real-time PCR-based test with high sensitivity and rapid turnaround time, providing results that are readily interpreted by clinicians. The Idylla platform proved straightforward to use with or without macrodissection. The method of handling the FFPE sections is distinct to Idylla and contrasts with the more usual method of placing the FFPE sections into a container. FFPE samples are loaded directly into single use cartridges with minimal sample preparation: histological sections (curls) for analysis are easily 'sandwiched' between the filter papers in the cassette. Potential drawbacks include the limited throughput (four samples per unit per day) and inability to retrieve samples and rescue an analysis if the system malfunctions mid-run. The Idylla platform would ideally be set up in a clean room close to where the paraffin sections are being prepared in a pathology laboratory and employed in clinical settings where the time saved by analysis on demand (compared with routine batch processing) would provide clinical and/or efficiency benefits. The Agena MassARRAY system can test from 1 to 384 samples on a chip (depending on the panels of tests and number of wells) and can process around 120 colorectal mutation tests per day.

###### Take home messages

-   Identification of mutations in *NRAS* and *BRAF* is important for treatment and prognosis in patients with colorectal cancer.

-   The Idylla NRAS-BRAF mutation test is as accurate as the widely used Agena MassARRAY.

-   The Idylla platform and Agena MassARRAY system are both highly configurable for low to high throughputs, but address different clinical and processing needs. The Idylla platform provides rapid analysis on demand, thus allowing pathology reports to integrate histology and mutation analysis, and treatment decisions to be made with minimum delay. The Agena MassARRAY system can process around 120 colorectal mutation tests per day.
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